Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Current Trends and Advances in the Diagnosis and Treatment of...
share announcement

Current Trends and Advances in the Diagnosis and Treatment of Gynecological Cancers

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2588

Special Issue Editor

Dr. Ozlen Saglam

E-Mail Website
Guest Editor
Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
Interests: gynecologic; breast pathology

Special Issue Information

Dear Colleagues,

The aim of the Special Issue is to provide an update in the diagnosis and treatment of ovarian, endometrial, cervical, and vulvar cancers. Invitations are extended to experts and investigators to discuss current histological and molecular classifications of gynecologic cancers and new treatment modalities with targeted treatment options in "original" and "review" papers. The main focus is on the new biomarkers and their clinical utilities in the diagnosis and prognosis of aggressive forms of gynecologic malignancies. Investigations about the precursor lesions of cancers with their molecular results and clinical tests for early detections of gynecological tumors are the priority. Immunotherapy and immunological pathways involved in the pathogenesis of gynecological tumors will be among the discussion points. Genetically inherited cancers/familial cancer types with information from next-generation sequencing are also within the scope of the issue.

Dr. Ozlen Saglam
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological cancer
  • biomarkers
  • immunotherapy
  • genetics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 4288 KiB  
Article
Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma
by Hillary P. Esplen, Richard K. Yang, Awdhesh Kalia, Zhenya Tang, Guilin Tang, L. Jeffrey Medeiros and Gokce A. Toruner
Life 2023, 13(11), 2192; https://doi.org/10.3390/life13112192 - 10 Nov 2023
Cited by 1 | Viewed by 1329
Abstract
Somatic copy number alterations (SCNAs) are frequently observed in high-grade ovarian serous carcinoma (HGOSC). However, their impact on gene expression levels has not been systematically assessed. In this study, we explored the relationship between recurrent SCNA and gene expression using The Cancer Genome [...] Read more.
Somatic copy number alterations (SCNAs) are frequently observed in high-grade ovarian serous carcinoma (HGOSC). However, their impact on gene expression levels has not been systematically assessed. In this study, we explored the relationship between recurrent SCNA and gene expression using The Cancer Genome Atlas Pan Cancer dataset (OSC, TCGA, PanCancer Atlas) to identify cancer-related genes in HGOSC. We then investigated any association between highly correlated cancer genes and clinicopathological parameters, including age of diagnosis, disease stage, overall survival (OS), and progression-free survival (PFS). A total of 772 genes with recurrent SCNAs were observed. SCNA and mRNA expression levels were highly correlated for 274 genes; 24 genes were classified as a Tier 1 gene in the Cancer Gene Census in the Catalogue of Somatic Mutations in Cancer (CGC-COSMIC). Of these, 11 Tier 1 genes had highly correlated SCNA and mRNA expression levels: TBL1XR1, PIK3CA, UBR5, EIF3E, RAD21, EXT1, RECQL4, KRAS, PRKACA, BRD4, and TPM4. There was no association between gene amplification and disease stage or PFS. EIF3E, RAD21, and EXT1 were more frequently amplified in younger patients, specifically those under the age of 55 years. Patients with tumors carrying PRKACA, BRD4, or TPM4 amplification were associated with a significantly shorter OS. RECQL4 amplification was more frequent in younger patients, and tumors with this amplification were associated with a significantly better OS. Full article
(This article belongs to the Special Issue Current Trends and Advances in the Diagnosis and Treatment of Gynecological Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 8817 KiB  
Review
Harnessing γδ T Cells against Human Gynecologic Cancers
by Jose R. Conejo-Garcia, Carmen M. Anadon, Luis U. Lopez-Bailon and Ricardo A. Chaurio
Life 2024, 14(3), 325; https://doi.org/10.3390/life14030325 - 29 Feb 2024
Viewed by 974
Abstract
Immuno-oncology has traditionally focused on conventional MHC-restricted αβ T cells. Yet, unconventional γδ T cells, which kill tumor cells in an MHC-unrestricted manner, display characteristics of effector activity and stemness without exhaustion and are nearly universally observed in human gynecologic malignancies, correlating with [...] Read more.
Immuno-oncology has traditionally focused on conventional MHC-restricted αβ T cells. Yet, unconventional γδ T cells, which kill tumor cells in an MHC-unrestricted manner, display characteristics of effector activity and stemness without exhaustion and are nearly universally observed in human gynecologic malignancies, correlating with improved outcomes. These cells do not have a clear counterpart in mice but are also found in the healthy female reproductive tract. Interventions that modulate their in vivo activity, or cellular therapies utilizing γδ T cells as an allogeneic, “off-the-shelf” platform (e.g., for chimeric antigen receptor expression) hold significant potential against challenging tumors like ovarian cancer, which has been stubbornly resistant to the immune checkpoint inhibitors that change the landscape of other human tumors. Here, we discuss recent discoveries on the specific populations of γδ T cells that infiltrate human gynecologic cancers, their anti-tumor activity, and the prospect of redirecting their effector function against tumor cells to develop a new generation of immunotherapies that extends beyond the traditional αβ T cell-centric view of the field. Full article
(This article belongs to the Special Issue Current Trends and Advances in the Diagnosis and Treatment of Gynecological Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop